APO Research
Talk to an analyst

APO RESEARCH · REPORT

Oligonucleotide Therapy-based Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Oligonucleotide Therapy-based Drug Market Analysis and Forecast 2026-2032

21 December 2025208 pages

Choose your research edition.

Industry ResearchOligonucleotide Therapy-based Drug Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Oligonucleotide Therapy-based Drug Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Oligonucleotide Therapy-based Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oligonucleotide Therapy-based Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Oligonucleotide Therapy-based Drug Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

The global Oligonucleotide Therapy-based Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Oligonucleotide Therapy-based Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Oligonucleotide Therapy-based Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Oligonucleotide Therapy-based Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Oligonucleotide Therapy-based Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Oligonucleotide Therapy-based Drug include Sobi, Novartis, Pfizer, Biogen, Sylentis, Silence Therapeutics, Secarna, Sarepta Therapeutics and Regulus Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Oligonucleotide Therapy-based Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Oligonucleotide Therapy-based Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Oligonucleotide Therapy-based Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Oligonucleotide Therapy-based Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Oligonucleotide Therapy-based Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Oligonucleotide Therapy-based Drug revenue, projected growth trends, production technology, application and end-user industry.

Oligonucleotide Therapy-based Drug Segment by Company

Sobi

Novartis

Pfizer

Biogen

Sylentis

Silence Therapeutics

Secarna

Sarepta Therapeutics

Regulus Therapeutics

ProQR

Nippon Shinyaku

Moderna Therapeutics

MiNA Therapeutics

Jazz Pharmaceuticals

Ionis Pharmaceuticals

Dicerna

CureVac

BioNTech

Arrowhead

Alnylam

Oligonucleotide Therapy-based Drug Segment by Type

mRNA

siRNA

Antisense Oligonucleotides (ASO)

Oligonucleotide Therapy-based Drug Segment by Application

hATTR

Neuromuscular Diseases

COVID-19

Other

Oligonucleotide Therapy-based Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide Therapy-based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide Therapy-based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide Therapy-based Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Oligonucleotide Therapy-based Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Oligonucleotide Therapy-based Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oligonucleotide Therapy-based Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Oligonucleotide Therapy-based Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. mRNA Major Player Table 3. siRNA Major Player Table 4. Antisense Oligonucleotides (ASO) Major Player Table 5. Global Oligonucleotide Therapy-based Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. hATTR Major Player Table 7. Neuromuscular Diseases Major Player Table 8. COVID-19 Major Player Table 9. Other Major Player Table 10. Oligonucleotide Therapy-based Drug Industry Trends Table 11. Oligonucleotide Therapy-based Drug Industry Drivers Table 12. Oligonucleotide Therapy-based Drug Industry Opportunities and Challenges Table 13. Oligonucleotide Therapy-based Drug Industry Restraints Table 14. Global Oligonucleotide Therapy-based Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Oligonucleotide Therapy-based Drug Market Share by Region (2021-2026) Table 17. Global Oligonucleotide Therapy-based Drug Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Oligonucleotide Therapy-based Drug Market Share by Region (2027-2032) Table 19. Global Oligonucleotide Therapy-based Drug Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Players (2021-2026) Table 21. Global Oligonucleotide Therapy-based Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Oligonucleotide Therapy-based Drug Key Players Headquarters & Area Served Table 23. Global Oligonucleotide Therapy-based Drug Players, Product Type & Application Table 24. Global Oligonucleotide Therapy-based Drug Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Oligonucleotide Therapy-based Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Oligonucleotide Therapy-based Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Oligonucleotide Therapy-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Oligonucleotide Therapy-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Type (2021-2026) Table 31. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Type (2027-2032) Table 32. Global Oligonucleotide Therapy-based Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Oligonucleotide Therapy-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Oligonucleotide Therapy-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Application (2021-2026) Table 36. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Application (2027-2032) Table 37. Sobi Company Information Table 38. Sobi Business Overview Table 39. Sobi Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Sobi Oligonucleotide Therapy-based Drug Product Portfolio Table 41. Sobi Recent Development Table 42. Novartis Company Information Table 43. Novartis Business Overview Table 44. Novartis Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Novartis Oligonucleotide Therapy-based Drug Product Portfolio Table 46. Novartis Recent Development Table 47. Pfizer Company Information Table 48. Pfizer Business Overview Table 49. Pfizer Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Pfizer Oligonucleotide Therapy-based Drug Product Portfolio Table 51. Pfizer Recent Development Table 52. Biogen Company Information Table 53. Biogen Business Overview Table 54. Biogen Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Biogen Oligonucleotide Therapy-based Drug Product Portfolio Table 56. Biogen Recent Development Table 57. Sylentis Company Information Table 58. Sylentis Business Overview Table 59. Sylentis Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Sylentis Oligonucleotide Therapy-based Drug Product Portfolio Table 61. Sylentis Recent Development Table 62. Silence Therapeutics Company Information Table 63. Silence Therapeutics Business Overview Table 64. Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Silence Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio Table 66. Silence Therapeutics Recent Development Table 67. Secarna Company Information Table 68. Secarna Business Overview Table 69. Secarna Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. Secarna Oligonucleotide Therapy-based Drug Product Portfolio Table 71. Secarna Recent Development Table 72. Sarepta Therapeutics Company Information Table 73. Sarepta Therapeutics Business Overview Table 74. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio Table 76. Sarepta Therapeutics Recent Development Table 77. Regulus Therapeutics Company Information Table 78. Regulus Therapeutics Business Overview Table 79. Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio Table 81. Regulus Therapeutics Recent Development Table 82. ProQR Company Information Table 83. ProQR Business Overview Table 84. ProQR Oligonucleotide Therapy-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. ProQR Oligonucleotide Therapy-based Drug Product Portfolio Table 86. ProQR Recent Development Table 87. Nippon Shinyaku Company Information Table 88. Nippon Shinyaku Business Overview Table 89. Nippon Shinyaku Oligonucleotide Therapy-based Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Portfolio Table 91. Nippon Shinyaku Recent Development Table 92. Moderna Therapeutics Company Information Table 93. Moderna Therapeutics Business Overview Table 94. Moderna Therapeutics Oligonucleotide Therapy-based Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio Table 96. Moderna Therapeutics Recent Development Table 97. MiNA Therapeutics Company Information Table 98. MiNA Therapeutics Business Overview Table 99. MiNA Therapeutics Oligonucleotide Therapy-based Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio Table 101. MiNA Therapeutics Recent Development Table 102. Jazz Pharmaceuticals Company Information Table 103. Jazz Pharmaceuticals Business Overview Table 104. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio Table 106. Jazz Pharmaceuticals Recent Development Table 107. Ionis Pharmaceuticals Company Information Table 108. Ionis Pharmaceuticals Business Overview Table 109. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio Table 111. Ionis Pharmaceuticals Recent Development Table 112. Dicerna Company Information Table 113. Dicerna Business Overview Table 114. Dicerna Oligonucleotide Therapy-based Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 115. Dicerna Oligonucleotide Therapy-based Drug Product Portfolio Table 116. Dicerna Recent Development Table 117. CureVac Company Information Table 118. CureVac Business Overview Table 119. CureVac Oligonucleotide Therapy-based Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 120. CureVac Oligonucleotide Therapy-based Drug Product Portfolio Table 121. CureVac Recent Development Table 122. BioNTech Company Information Table 123. BioNTech Business Overview Table 124. BioNTech Oligonucleotide Therapy-based Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 125. BioNTech Oligonucleotide Therapy-based Drug Product Portfolio Table 126. BioNTech Recent Development Table 127. Arrowhead Company Information Table 128. Arrowhead Business Overview Table 129. Arrowhead Oligonucleotide Therapy-based Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 130. Arrowhead Oligonucleotide Therapy-based Drug Product Portfolio Table 131. Arrowhead Recent Development Table 132. Alnylam Company Information Table 133. Alnylam Business Overview Table 134. Alnylam Oligonucleotide Therapy-based Drug Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 135. Alnylam Oligonucleotide Therapy-based Drug Product Portfolio Table 136. Alnylam Recent Development Table 137. North America Oligonucleotide Therapy-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 138. North America Oligonucleotide Therapy-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 139. North America Oligonucleotide Therapy-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 140. North America Oligonucleotide Therapy-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 141. North America Oligonucleotide Therapy-based Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. North America Oligonucleotide Therapy-based Drug Revenue by Country (2021-2026) & (US$ Million) Table 143. North America Oligonucleotide Therapy-based Drug Revenue by Country (US$ Million) & (2027-2032) Table 144. Europe Oligonucleotide Therapy-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 145. Europe Oligonucleotide Therapy-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 146. Europe Oligonucleotide Therapy-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 147. Europe Oligonucleotide Therapy-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 148. Europe Oligonucleotide Therapy-based Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 149. Europe Oligonucleotide Therapy-based Drug Revenue by Country (2021-2026) & (US$ Million) Table 150. Europe Oligonucleotide Therapy-based Drug Revenue by Country (US$ Million) & (2027-2032) Table 151. China Oligonucleotide Therapy-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 152. China Oligonucleotide Therapy-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 153. China Oligonucleotide Therapy-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 154. China Oligonucleotide Therapy-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 155. Asia Oligonucleotide Therapy-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 156. Asia Oligonucleotide Therapy-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 157. Asia Oligonucleotide Therapy-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 158. Asia Oligonucleotide Therapy-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 159. Asia Oligonucleotide Therapy-based Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 160. Asia Oligonucleotide Therapy-based Drug Revenue by Region (US$ Million) & (2021-2026) Table 161. Asia Oligonucleotide Therapy-based Drug Revenue by Region (US$ Million) & (2027-2032) Table 162. SAMEA Oligonucleotide Therapy-based Drug Revenue by Type (2021-2026) & (US$ Million) Table 163. SAMEA Oligonucleotide Therapy-based Drug Revenue by Type (2027-2032) & (US$ Million) Table 164. SAMEA Oligonucleotide Therapy-based Drug Revenue by Application (2021-2026) & (US$ Million) Table 165. SAMEA Oligonucleotide Therapy-based Drug Revenue by Application (2027-2032) & (US$ Million) Table 166. SAMEA Oligonucleotide Therapy-based Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 167. SAMEA Oligonucleotide Therapy-based Drug Revenue by Country (2021-2026) & (US$ Million) Table 168. SAMEA Oligonucleotide Therapy-based Drug Revenue by Country (US$ Million) & (2027-2032) Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. Oligonucleotide Therapy-based Drug Image Figure 2. Global Oligonucleotide Therapy-based Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Oligonucleotide Therapy-based Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. mRNA Image Figure 5. siRNA Image Figure 6. Antisense Oligonucleotides (ASO) Image Figure 7. Global Oligonucleotide Therapy-based Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Oligonucleotide Therapy-based Drug Market Size Share 2021 VS 2025 VS 2032 Figure 9. hATTR Image Figure 10. Neuromuscular Diseases Image Figure 11. COVID-19 Image Figure 12. Other Image Figure 13. Global Oligonucleotide Therapy-based Drug Market Size (US$ Million) & (2021-2032) Figure 14. Global Oligonucleotide Therapy-based Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Oligonucleotide Therapy-based Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Oligonucleotide Therapy-based Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Oligonucleotide Therapy-based Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Oligonucleotide Therapy-based Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Type (2021-2032) Figure 21. Global Oligonucleotide Therapy-based Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Application (2021-2032) Figure 24. North America Oligonucleotide Therapy-based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Oligonucleotide Therapy-based Drug Revenue Share by Type (2021-2032) Figure 26. North America Oligonucleotide Therapy-based Drug Revenue Share by Application (2021-2032) Figure 27. North America Oligonucleotide Therapy-based Drug Revenue Share by Country (2021-2032) Figure 28. United States Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Oligonucleotide Therapy-based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Oligonucleotide Therapy-based Drug Revenue Share by Type (2021-2032) Figure 33. Europe Oligonucleotide Therapy-based Drug Revenue Share by Application (2021-2032) Figure 34. Europe Oligonucleotide Therapy-based Drug Revenue Share by Country (2021-2032) Figure 35. Germany Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Oligonucleotide Therapy-based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Oligonucleotide Therapy-based Drug Revenue Share by Type (2021-2032) Figure 45. China Oligonucleotide Therapy-based Drug Revenue Share by Application (2021-2032) Figure 46. Asia Oligonucleotide Therapy-based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Oligonucleotide Therapy-based Drug Revenue Share by Type (2021-2032) Figure 48. Asia Oligonucleotide Therapy-based Drug Revenue Share by Application (2021-2032) Figure 49. Asia Oligonucleotide Therapy-based Drug Revenue Share by Region (2021-2032) Figure 50. Japan Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Oligonucleotide Therapy-based Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Oligonucleotide Therapy-based Drug Revenue Share by Type (2021-2032) Figure 58. SAMEA Oligonucleotide Therapy-based Drug Revenue Share by Application (2021-2032) Figure 59. SAMEA Oligonucleotide Therapy-based Drug Revenue Share by Country (2021-2032) Figure 60. Brazil Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Oligonucleotide Therapy-based Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • mRNA
  • siRNA
  • Antisense Oligonucleotides (ASO)
Applications
  • hATTR
  • Neuromuscular Diseases
  • COVID-19
  • Other
Companies covered
  • Sobi
  • Novartis
  • Pfizer
  • Biogen
  • Sylentis
  • Silence Therapeutics
  • Secarna
  • Sarepta Therapeutics
  • Regulus Therapeutics
  • ProQR
  • Nippon Shinyaku
  • Moderna Therapeutics
  • MiNA Therapeutics
  • Jazz Pharmaceuticals
  • Ionis Pharmaceuticals
  • Dicerna
  • CureVac
  • BioNTech
  • Arrowhead
  • Alnylam

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Oligonucleotide Therapy-based Drug Market by Type
  3. 1.2.1 Global Oligonucleotide Therapy-based Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 mRNA
  5. 1.2.3 siRNA
  6. 1.2.4 Antisense Oligonucleotides (ASO)
  7. 1.3 Oligonucleotide Therapy-based Drug Market by Application
  8. 1.3.1 Global Oligonucleotide Therapy-based Drug Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 hATTR
  10. 1.3.3 Neuromuscular Diseases
  11. 1.3.4 COVID-19
  12. 1.3.5 Other
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Oligonucleotide Therapy-based Drug Market Dynamics
  1. 2.1 Oligonucleotide Therapy-based Drug Industry Trends
  2. 2.2 Oligonucleotide Therapy-based Drug Industry Drivers
  3. 2.3 Oligonucleotide Therapy-based Drug Industry Opportunities and Challenges
  4. 2.4 Oligonucleotide Therapy-based Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Oligonucleotide Therapy-based Drug Market Perspective (2021-2032)
  2. 3.2 Global Oligonucleotide Therapy-based Drug Growth Trends by Region
  3. 3.2.1 Global Oligonucleotide Therapy-based Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Oligonucleotide Therapy-based Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Oligonucleotide Therapy-based Drug Revenue by Players
  2. 4.1.1 Global Oligonucleotide Therapy-based Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Oligonucleotide Therapy-based Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Oligonucleotide Therapy-based Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Oligonucleotide Therapy-based Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Oligonucleotide Therapy-based Drug Key Players Headquarters & Area Served
  7. 4.4 Global Oligonucleotide Therapy-based Drug Players, Product Type & Application
  8. 4.5 Global Oligonucleotide Therapy-based Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Oligonucleotide Therapy-based Drug Market CR5 and HHI
  11. 4.6.3 2025 Oligonucleotide Therapy-based Drug Tier 1, Tier 2, and Tier 3
5 Oligonucleotide Therapy-based Drug Market Size by Type
  1. 5.1 Global Oligonucleotide Therapy-based Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Oligonucleotide Therapy-based Drug Revenue by Type (2021-2032)
  3. 5.3 Global Oligonucleotide Therapy-based Drug Revenue Market Share by Type (2021-2032)
6 Oligonucleotide Therapy-based Drug Market Size by Application
  1. 6.1 Global Oligonucleotide Therapy-based Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Oligonucleotide Therapy-based Drug Revenue by Application (2021-2032)
  3. 6.3 Global Oligonucleotide Therapy-based Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Sobi
  2. 7.1.1 Sobi Company Information
  3. 7.1.2 Sobi Business Overview
  4. 7.1.3 Sobi Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Sobi Oligonucleotide Therapy-based Drug Product Portfolio
  6. 7.1.5 Sobi Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis Oligonucleotide Therapy-based Drug Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Oligonucleotide Therapy-based Drug Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 Biogen
  20. 7.4.1 Biogen Company Information
  21. 7.4.2 Biogen Business Overview
  22. 7.4.3 Biogen Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Biogen Oligonucleotide Therapy-based Drug Product Portfolio
  24. 7.4.5 Biogen Recent Developments
  25. 7.5 Sylentis
  26. 7.5.1 Sylentis Company Information
  27. 7.5.2 Sylentis Business Overview
  28. 7.5.3 Sylentis Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sylentis Oligonucleotide Therapy-based Drug Product Portfolio
  30. 7.5.5 Sylentis Recent Developments
  31. 7.6 Silence Therapeutics
  32. 7.6.1 Silence Therapeutics Company Information
  33. 7.6.2 Silence Therapeutics Business Overview
  34. 7.6.3 Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Silence Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
  36. 7.6.5 Silence Therapeutics Recent Developments
  37. 7.7 Secarna
  38. 7.7.1 Secarna Company Information
  39. 7.7.2 Secarna Business Overview
  40. 7.7.3 Secarna Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Secarna Oligonucleotide Therapy-based Drug Product Portfolio
  42. 7.7.5 Secarna Recent Developments
  43. 7.8 Sarepta Therapeutics
  44. 7.8.1 Sarepta Therapeutics Company Information
  45. 7.8.2 Sarepta Therapeutics Business Overview
  46. 7.8.3 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
  48. 7.8.5 Sarepta Therapeutics Recent Developments
  49. 7.9 Regulus Therapeutics
  50. 7.9.1 Regulus Therapeutics Company Information
  51. 7.9.2 Regulus Therapeutics Business Overview
  52. 7.9.3 Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
  54. 7.9.5 Regulus Therapeutics Recent Developments
  55. 7.10 ProQR
  56. 7.10.1 ProQR Company Information
  57. 7.10.2 ProQR Business Overview
  58. 7.10.3 ProQR Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 ProQR Oligonucleotide Therapy-based Drug Product Portfolio
  60. 7.10.5 ProQR Recent Developments
  61. 7.11 Nippon Shinyaku
  62. 7.11.1 Nippon Shinyaku Company Information
  63. 7.11.2 Nippon Shinyaku Business Overview
  64. 7.11.3 Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Portfolio
  66. 7.11.5 Nippon Shinyaku Recent Developments
  67. 7.12 Moderna Therapeutics
  68. 7.12.1 Moderna Therapeutics Company Information
  69. 7.12.2 Moderna Therapeutics Business Overview
  70. 7.12.3 Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
  72. 7.12.5 Moderna Therapeutics Recent Developments
  73. 7.13 MiNA Therapeutics
  74. 7.13.1 MiNA Therapeutics Company Information
  75. 7.13.2 MiNA Therapeutics Business Overview
  76. 7.13.3 MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  77. 7.13.4 MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
  78. 7.13.5 MiNA Therapeutics Recent Developments
  79. 7.14 Jazz Pharmaceuticals
  80. 7.14.1 Jazz Pharmaceuticals Company Information
  81. 7.14.2 Jazz Pharmaceuticals Business Overview
  82. 7.14.3 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio
  84. 7.14.5 Jazz Pharmaceuticals Recent Developments
  85. 7.15 Ionis Pharmaceuticals
  86. 7.15.1 Ionis Pharmaceuticals Company Information
  87. 7.15.2 Ionis Pharmaceuticals Business Overview
  88. 7.15.3 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio
  90. 7.15.5 Ionis Pharmaceuticals Recent Developments
  91. 7.16 Dicerna
  92. 7.16.1 Dicerna Company Information
  93. 7.16.2 Dicerna Business Overview
  94. 7.16.3 Dicerna Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Dicerna Oligonucleotide Therapy-based Drug Product Portfolio
  96. 7.16.5 Dicerna Recent Developments
  97. 7.17 CureVac
  98. 7.17.1 CureVac Company Information
  99. 7.17.2 CureVac Business Overview
  100. 7.17.3 CureVac Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  101. 7.17.4 CureVac Oligonucleotide Therapy-based Drug Product Portfolio
  102. 7.17.5 CureVac Recent Developments
  103. 7.18 BioNTech
  104. 7.18.1 BioNTech Company Information
  105. 7.18.2 BioNTech Business Overview
  106. 7.18.3 BioNTech Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  107. 7.18.4 BioNTech Oligonucleotide Therapy-based Drug Product Portfolio
  108. 7.18.5 BioNTech Recent Developments
  109. 7.19 Arrowhead
  110. 7.19.1 Arrowhead Company Information
  111. 7.19.2 Arrowhead Business Overview
  112. 7.19.3 Arrowhead Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  113. 7.19.4 Arrowhead Oligonucleotide Therapy-based Drug Product Portfolio
  114. 7.19.5 Arrowhead Recent Developments
  115. 7.20 Alnylam
  116. 7.20.1 Alnylam Company Information
  117. 7.20.2 Alnylam Business Overview
  118. 7.20.3 Alnylam Oligonucleotide Therapy-based Drug Revenue and Gross Margin (2021-2026)
  119. 7.20.4 Alnylam Oligonucleotide Therapy-based Drug Product Portfolio
  120. 7.20.5 Alnylam Recent Developments
8 North America
  1. 8.1 North America Oligonucleotide Therapy-based Drug Revenue (2021-2032)
  2. 8.2 North America Oligonucleotide Therapy-based Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Oligonucleotide Therapy-based Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Oligonucleotide Therapy-based Drug Revenue by Type (2027-2032)
  5. 8.3 North America Oligonucleotide Therapy-based Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Oligonucleotide Therapy-based Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Oligonucleotide Therapy-based Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Oligonucleotide Therapy-based Drug Revenue by Application (2027-2032)
  9. 8.5 North America Oligonucleotide Therapy-based Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Oligonucleotide Therapy-based Drug Revenue by Country
  11. 8.6.1 North America Oligonucleotide Therapy-based Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Oligonucleotide Therapy-based Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Oligonucleotide Therapy-based Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Oligonucleotide Therapy-based Drug Revenue (2021-2032)
  2. 9.2 Europe Oligonucleotide Therapy-based Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Oligonucleotide Therapy-based Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Oligonucleotide Therapy-based Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Oligonucleotide Therapy-based Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Oligonucleotide Therapy-based Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Oligonucleotide Therapy-based Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Oligonucleotide Therapy-based Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Oligonucleotide Therapy-based Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Oligonucleotide Therapy-based Drug Revenue by Country
  11. 9.6.1 Europe Oligonucleotide Therapy-based Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Oligonucleotide Therapy-based Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Oligonucleotide Therapy-based Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Oligonucleotide Therapy-based Drug Revenue (2021-2032)
  2. 10.2 China Oligonucleotide Therapy-based Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Oligonucleotide Therapy-based Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Oligonucleotide Therapy-based Drug Revenue by Type (2027-2032)
  5. 10.3 China Oligonucleotide Therapy-based Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Oligonucleotide Therapy-based Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Oligonucleotide Therapy-based Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Oligonucleotide Therapy-based Drug Revenue by Application (2027-2032)
  9. 10.5 China Oligonucleotide Therapy-based Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Oligonucleotide Therapy-based Drug Revenue (2021-2032)
  2. 11.2 Asia Oligonucleotide Therapy-based Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Oligonucleotide Therapy-based Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Oligonucleotide Therapy-based Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Oligonucleotide Therapy-based Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Oligonucleotide Therapy-based Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Oligonucleotide Therapy-based Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Oligonucleotide Therapy-based Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Oligonucleotide Therapy-based Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Oligonucleotide Therapy-based Drug Revenue by Country
  11. 11.6.1 Asia Oligonucleotide Therapy-based Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Oligonucleotide Therapy-based Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Oligonucleotide Therapy-based Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Oligonucleotide Therapy-based Drug Revenue (2021-2032)
  2. 12.2 SAMEA Oligonucleotide Therapy-based Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Oligonucleotide Therapy-based Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Oligonucleotide Therapy-based Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Oligonucleotide Therapy-based Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Oligonucleotide Therapy-based Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Oligonucleotide Therapy-based Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Oligonucleotide Therapy-based Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Oligonucleotide Therapy-based Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Oligonucleotide Therapy-based Drug Revenue by Country
  11. 12.6.1 SAMEA Oligonucleotide Therapy-based Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Oligonucleotide Therapy-based Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Oligonucleotide Therapy-based Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst